U.S. markets close in 1 hour 2 minutes

Vaxcyte, Inc. (PCVX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
45.01-0.49 (-1.07%)
As of 02:57PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close45.50
Bid44.77 x 1000
Ask44.84 x 1000
Day's Range44.76 - 46.14
52 Week Range16.78 - 47.67
Avg. Volume1,246,904
Market Cap3.555B
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-2.20
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est62.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PCVX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vaxcyte, Inc.
    ITOS: Lowering target price to $20.00ITEOS THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    2 days agoArgus Research
View more
  • GlobeNewswire

    Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update

    -- Vaxcyte Reported Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 18-64 -- -- Phase 1/2 Study Met Safety, Tolerability and Immunogenicity Objectives; Findings Indicate a Potential Best-in-Class Profile for VAX-24 -- -- Company Advancing VAX-24 in Adult and Pediatric Populations with Submission of Infant Investigational New Drug

  • GlobeNewswire

    Vaxcyte to Present at Upcoming Investor Conferences

    SAN CARLOS, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in and host one-on-one meetings at the following investor conferences: Guggenheim 4th Annual Immunology and Neurology ConferenceNovember 14-15, 2022 Fireside Chat will take place live on Monday, November 14 at 1:35

  • The Wall Street Journal

    Drugmakers Fight Over Lucrative Pneumonia Vaccines

    The growing $7 billion market is currently dominated by Pfizer, and rivals’ interest in winning more of the business shows the pharmaceutical industry’s renewed focus on vaccines.